source
- Tyra Biosciences reports Phase 2 success in low-risk bladder cancer, plans pivotal trialTyra Biosciences announced that its experimental therapy for low‑risk bladder cancer has produced encouraging results in a Phase 2 study. The company said the data, released on Wednesday, represen…
- Kura Oncology launches Caspian Therapeutics with $50M funding to develop next-generation diabetes drugKura Oncology has created a new biotech called Caspian Therapeutics and secured $50 million in financing to advance a next-generation diabetes treatment. The spinout will focus on KO-7246, a highl…